

Evaluation of Convalescent Plasma for Ebola Virus Disease

New England Journal of Medicine

374, 33-42

DOI: [10.1056/nejmoa1511812](https://doi.org/10.1056/nejmoa1511812)

Citation Report

#	ARTICLE	IF	CITATIONS
1	West Africa 2013: Re-examining Ebola. <i>Microbiology Spectrum</i> , 2016, 4, .	1.2	16
3	Critical role of ethics in clinical management and public health response to the West Africa Ebola epidemic. <i>Risk Management and Healthcare Policy</i> , 2016, 9, 55.	1.2	8
4	Electrolyte and Metabolic Disturbances in Ebola Patients during a Clinical Trial, Guinea, 2015. <i>Emerging Infectious Diseases</i> , 2016, 22, .	2.0	13
5	Use of Plasma Therapy for Severe Fever with Thrombocytopenia Syndrome Encephalopathy. <i>Emerging Infectious Diseases</i> , 2016, 22, 1306-1308.	2.0	18
6	Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea. <i>PLoS Medicine</i> , 2016, 13, e1001967.	3.9	382
7	Open drug discovery for the Zika virus. <i>F1000Research</i> , 2016, 5, 150.	0.8	50
8	Trial of blood-based Ebola therapy disappoints. <i>Nature</i> , 2016, , .	13.7	0
9	Discovery and Description of Ebola Zaire Virus in 1976 and Relevance to the West African Epidemic During 2013-2016. <i>Journal of Infectious Diseases</i> , 2016, 214, S93-S101.	1.9	72
10	REACTing: the French response to infectious disease crises. <i>Lancet</i> , The, 2016, 387, 2183-2185.	6.3	14
11	Maladie À virus Ebola: actualités thérapeutiques. <i>Journal Des Anti-infectieux</i> , 2016, 18, 117-125.	0.1	2
12	Ebola virus disease and critical illness. <i>Critical Care</i> , 2016, 20, 217.	2.5	97
13	A Randomized, Controlled Trial of ZMapp for Ebola Virus Infection. <i>New England Journal of Medicine</i> , 2016, 375, 1448-1456.	13.9	429
14	Convalescent Ebola plasma: assessing neutralizing antibodies at the right stage. <i>Vox Sanguinis</i> , 2016, 111, 456-457.	0.7	1
15	Passive Immunotherapy: Assessment of Convalescent Serum Against Ebola Virus Makona Infection in Nonhuman Primates. <i>Journal of Infectious Diseases</i> , 2016, 214, S367-S374.	1.9	36
16	Blood transfusion in 2016: Towards a "Nouvelle Vague" therapy?. <i>Presse Medicale</i> , 2016, 45, e243-e245.	0.8	3
17	Neurological Complications of Ebola Virus Infection. <i>Neurotherapeutics</i> , 2016, 13, 461-470.	2.1	44
18	Epidemiology and Management of the 2013-16 West African Ebola Outbreak. <i>Annual Review of Virology</i> , 2016, 3, 147-171.	3.0	28
19	Efficacy of Convalescent Plasma in Relation to Dose of Ebola Virus Antibodies. <i>New England Journal of Medicine</i> , 2016, 375, 2307-2309.	13.9	68

#	ARTICLE	IF	CITATIONS
20	Organizing the Donation of Convalescent Plasma for a Therapeutic Clinical Trial on Ebola Virus Disease: The Experience in Guinea. <i>American Journal of Tropical Medicine and Hygiene</i> , 2016, 95, 647-653.	0.6	10
21	In silico and in vitro methods to identify ebola virus VP35-dsRNA inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2016, 24, 5388-5392.	1.4	15
22	Human Survivors of Disease Outbreaks Caused by Ebola or Marburg Virus Exhibit Cross-Reactive and Long-Lived Antibody Responses. <i>Vaccine Journal</i> , 2016, 23, 717-724.	3.2	40
24	Antiviral therapeutics for the treatment of Ebola virus infection. <i>Current Opinion in Pharmacology</i> , 2016, 30, 138-143.	1.7	17
28	Ebola Virus Disease: Therapeutic and Potential Preventative Opportunities. <i>Microbiology Spectrum</i> , 2016, 4, .	1.2	1
29	Modernising epidemic science: enabling patient-centred research during epidemics. <i>BMC Medicine</i> , 2016, 14, 212.	2.3	39
30	Cell-targeting antibodies in immunity to Ebola. <i>Pathogens and Disease</i> , 2016, 74, ftw021.	0.8	11
31	Convalescent Plasma for Ebola Virus Disease. <i>New England Journal of Medicine</i> , 2016, 374, 2498-2500.	13.9	16
32	The 2014â€“2015 Ebola outbreak in West Africa: Hands On. <i>Antimicrobial Resistance and Infection Control</i> , 2016, 5, .	1.5	55
33	Immunobiology of Ebola and Lassa virus infections. <i>Nature Reviews Immunology</i> , 2017, 17, 195-207.	10.6	95
34	Ebola: lessons learned. <i>Paediatrics and Child Health (United Kingdom)</i> , 2017, 27, 128-134.	0.2	2
35	Clinical Features and Outcome of Ebola Virus Disease in Pediatric Patients: A Retrospective Case Series. <i>Journal of Pediatrics</i> , 2017, 182, 378-381.e1.	0.9	15
36	An update on the 2014 Ebola outbreak in Western Africa. <i>Asian Pacific Journal of Tropical Medicine</i> , 2017, 10, 6-10.	0.4	15
37	Experimental Therapies for Ebola Virus Disease: What Have We Learned?. <i>Journal of Infectious Diseases</i> , 2017, 215, jiw496.	1.9	23
38	Multidisciplinary assessment of post-Ebola sequelae in Guinea (Postebogui): an observational cohort study. <i>Lancet Infectious Diseases</i> , The, 2017, 17, 545-552.	4.6	96
39	Will There Be a Cure for Ebola?. <i>Annual Review of Pharmacology and Toxicology</i> , 2017, 57, 329-348.	4.2	40
40	Vaccine development for emerging virulent infectious diseases. <i>Vaccine</i> , 2017, 35, 5437-5443.	1.7	28
41	Strengthening Health Systems Through International Blood Product Sharing Agreements. <i>Health Security</i> , 2017, 15, 110-117.	0.9	3

#	ARTICLE	IF	CITATIONS
42	Comparison of platform technologies for assaying antibody to Ebola virus. <i>Vaccine</i> , 2017, 35, 1347-1352.	1.7	28
43	Multivalent Glycosylated Nanostructures To Inhibit Ebola Virus Infection. <i>Journal of the American Chemical Society</i> , 2017, 139, 6018-6025.	6.6	104
44	Ebola virus disease and pregnancy: A review of the current knowledge of Ebola virus pathogenesis, maternal, and neonatal outcomes. <i>Birth Defects Research</i> , 2017, 109, 353-362.	0.8	61
45	Offering patients more: how the West Africa Ebola outbreak can shape innovation in therapeutic research for emerging and epidemic infections. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2017, 372, 20160294.	1.8	10
46	Emerging sexually transmitted viral infections: 1. Review of Ebola virus disease. <i>International Journal of STD and AIDS</i> , 2017, 28, 1352-1359.	0.5	5
47	How to treat Ebola virus infections? A lesson from the field. <i>Current Opinion in Virology</i> , 2017, 24, 9-15.	2.6	15
48	Use of human immunoglobulins as an anti-infective treatment: the experience so far and their possible re-emerging role. <i>Expert Review of Anti-Infective Therapy</i> , 2017, 15, 585-604.	2.0	28
49	Insights from clinical research completed during the west Africa Ebola virus disease epidemic. <i>Lancet Infectious Diseases</i> , The, 2017, 17, e280-e292.	4.6	69
50	The Role of the Laboratory and Transfusion Service in the Management of Ebola Virus Disease. <i>Transfusion Medicine Reviews</i> , 2017, 31, 149-153.	0.9	6
51	Repurposed Therapeutic Agents Targeting the Ebola Virus: A Systematic Review. <i>Current Therapeutic Research</i> , 2017, 84, 10-21.	0.5	44
52	Convalescent Plasma and the Dose of Ebola Virus Antibodies. <i>New England Journal of Medicine</i> , 2017, 376, 1296-1297.	13.9	6
53	The ongoing evolution of antibody-based treatments for Ebola virus infection. <i>Immunotherapy</i> , 2017, 9, 435-450.	1.0	20
54	Biochemical testing in a laboratory tent and semi-intensive care of Ebola patients on-site in a remote part of Guinea: a paradigm shift based on a bleach-sensitive point-of-care device. <i>Clinical Chemistry and Laboratory Medicine</i> , 2017, 55, 1881-1890.	1.4	5
55	Use of convalescent plasma in Ebola virus infection. <i>Transfusion and Apheresis Science</i> , 2017, 56, 31-34.	0.5	26
56	Profile and reintegration experience of Ebola survivors in Guinea: a cross-sectional study. <i>Tropical Medicine and International Health</i> , 2017, 22, 254-260.	1.0	11
57	The Pathogenesis of Ebola Virus Disease. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2017, 12, 387-418.	9.6	266
58	Discovering Drugs for the Treatment of Ebola Virus. <i>Current Treatment Options in Infectious Diseases</i> , 2017, 9, 299-317.	0.8	51
59	We Can Do Better – Improving Outcomes in the Midst of an Emergency. <i>New England Journal of Medicine</i> , 2017, 377, 1482-1484.	13.9	13

#	ARTICLE	IF	CITATIONS
61	Clinical Evaluation of Ebola Virus Disease Therapeutics. Trends in Molecular Medicine, 2017, 23, 820-830.	3.5	17
62	Emerging Infections and Pertinent Infections Related to Travel for Patients with Primary Immunodeficiencies. Journal of Clinical Immunology, 2017, 37, 650-692.	2.0	6
63	Ebola Virus Disease in Humans: Pathophysiology and Immunity. Current Topics in Microbiology and Immunology, 2017, 411, 141-169.	0.7	31
64	Clinical Management of Ebola Virus Disease Patients in Low-Resource Settings. Current Topics in Microbiology and Immunology, 2017, 411, 93-113.	0.7	5
65	Ebola: Anatomy of an Epidemic. Annual Review of Medicine, 2017, 68, 359-370.	5.0	44
66	Viral Hemorrhagic Fevers. , 2017, , 1110-1118.e2.		0
68	Toward an Effective Ebola Virus Vaccine. Annual Review of Medicine, 2017, 68, 371-386.	5.0	29
69	Apheresis for collection of Ebola convalescent plasma in Liberia. Journal of Clinical Apheresis, 2017, 32, 175-181.	0.7	16
70	Accelerating Drug Development: Antiviral Therapies for Emerging Viruses as a Model. Annual Review of Pharmacology and Toxicology, 2017, 57, 155-169.	4.2	23
71	Ebola virus disease: An update on current prevention and management strategies. Journal of Clinical Virology, 2017, 86, 5-13.	1.6	25
72	Evaluation of convalescent whole blood for treating Ebola Virus Disease in Freetown, Sierra Leone. Journal of Infection, 2017, 74, 302-309.	1.7	94
73	Marburg- and Ebolaviruses. Current Topics in Microbiology and Immunology, 2017, , .	0.7	4
74	Therapeutics Against Filovirus Infection. Current Topics in Microbiology and Immunology, 2017, 411, 263-290.	0.7	3
76	Ebola Virus Glycoprotein Induces an Innate Immune Response In vivo via TLR4. Frontiers in Microbiology, 2017, 8, 1571.	1.5	56
77	Mortality among PCR negative admitted Ebola suspects during the 2014/15 outbreak in Conakry, Guinea: A retrospective cohort study. PLoS ONE, 2017, 12, e0180070.	1.1	5
78	Challenges in preparing and implementing a clinical trial at field level in an Ebola emergency: A case study in Guinea, West Africa. PLoS Neglected Tropical Diseases, 2017, 11, e0005545.	1.3	17
79	Protected to death: systematic exclusion of pregnant women from Ebola virus disease trials. Reproductive Health, 2017, 14, 172.	1.2	69
80	Therapeutic Antibodies for Biodefense. Advances in Experimental Medicine and Biology, 2017, 1053, 173-205.	0.8	7

#	ARTICLE	IF	CITATIONS
82	Operational Research during the Ebola Emergency. <i>Emerging Infectious Diseases</i> , 2017, 23, 1057-1062.	2.0	6
83	ZMapp. , 2017, , 49-62.		1
84	Maternal and perinatal outcomes in pregnant women with suspected Ebola virus disease in Sierra Leone, 2014. <i>International Journal of Gynecology and Obstetrics</i> , 2018, 142, 71-77.	1.0	15
85	Anti-Ebola Virus Antibody Levels in Convalescent Plasma and Viral Load After Plasma Infusion in Patients With Ebola Virus Disease. <i>Journal of Infectious Diseases</i> , 2018, 218, 555-562.	1.9	34
86	Rigorous Clinical Trial Design in Public Health Emergencies Is Essential. <i>Clinical Infectious Diseases</i> , 2018, 66, 1467-1469.	2.9	20
88	Post-exposure treatments for Ebola and Marburg virus infections. <i>Nature Reviews Drug Discovery</i> , 2018, 17, 413-434.	21.5	104
89	Initiation and publication time-lags of treatment trials for Ebola virus disease. <i>Lancet Infectious Diseases</i> , The, 2018, 18, 28-29.	4.6	4
90	The role of adjuvant immunomodulatory agents for treatment of severe influenza. <i>Antiviral Research</i> , 2018, 150, 202-216.	1.9	82
91	A Serological Point-of-Care Test for the Detection of IgG Antibodies against Ebola Virus in Human Survivors. <i>ACS Nano</i> , 2018, 12, 63-73.	7.3	163
92	Detection, characterization, and enrollment of donors of Ebola convalescent plasma in Sierra Leone. <i>Transfusion</i> , 2018, 58, 1289-1298.	0.8	23
93	Transmission, Human Population, and Pathogenicity: the Ebola Case in Point. <i>Microbiology Spectrum</i> , 2018, 6, .	1.2	6
94	What Is the Predictive Value of Animal Models for Vaccine Efficacy in Humans?. <i>Cold Spring Harbor Perspectives in Biology</i> , 2018, 10, a028902.	2.3	31
95	Treatment-focused Ebola trials, supportive care and future of filovirus care. <i>Expert Review of Anti-Infective Therapy</i> , 2018, 16, 67-76.	2.0	9
96	Ebola virus disease: an update on post-exposure prophylaxis. <i>Lancet Infectious Diseases</i> , The, 2018, 18, e183-e192.	4.6	112
98	Postface: Meaning of the Experiment and Implications of the Experience. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 79, S69-S73.	0.9	0
99	Novel amodiaquine derivatives potently inhibit Ebola virus infection. <i>Antiviral Research</i> , 2018, 160, 175-182.	1.9	20
100	Ebola viral dynamics in nonhuman primates provides insights into virus immuno-pathogenesis and antiviral strategies. <i>Nature Communications</i> , 2018, 9, 4013.	5.8	54
101	Blood transfusion in sub-Saharan Africa: understanding the missing gap and responding to present and future challenges. <i>Vox Sanguinis</i> , 2018, 113, 726-736.	0.7	43

#	ARTICLE	IF	CITATIONS
102	Generation of therapeutic antisera for emerging viral infections. <i>Npj Vaccines</i> , 2018, 3, 42.	2.9	10
103	What motivates Ebola survivors to donate plasma during an emergency clinical trial? The case of Ebola-Tx in Guinea. <i>PLoS Neglected Tropical Diseases</i> , 2018, 12, e0006885.	1.3	9
104	Vaccine-elicited receptor-binding site antibodies neutralize two New World hemorrhagic fever arenaviruses. <i>Nature Communications</i> , 2018, 9, 1884.	5.8	40
105	Human Polyclonal Antibodies Produced by Transchromosomal Cattle Provide Partial Protection Against Lethal Zaire Ebolavirus Challenge in Rhesus Macaques. <i>Journal of Infectious Diseases</i> , 2018, 218, S658-S661.	1.9	10
106	Intensive care support and clinical outcomes of patients with Ebola virus disease (EVD) in West Africa. <i>Intensive Care Medicine</i> , 2018, 44, 1266-1275.	3.9	16
107	Ebola Immunity: Gaining a Winning Position in Lightning Chess. <i>Journal of Immunology</i> , 2018, 201, 833-842.	0.4	19
109	Ebola Virus: Pathogenesis and Countermeasure Development. <i>Annual Review of Virology</i> , 2019, 6, 435-458.	3.0	50
110	From therapeutic antibodies to immune complex vaccines. <i>Npj Vaccines</i> , 2019, 4, 2.	2.9	44
111	Epidemiological characteristics, clinical manifestations, and treatment outcome of 139 paediatric Ebola patients treated at a Sierra Leone Ebola treatment center. <i>BMC Infectious Diseases</i> , 2019, 19, 81.	1.3	5
112	International Biological Reference Preparations for Epidemic Infectious Diseases. <i>Emerging Infectious Diseases</i> , 2019, 25, 205-211.	2.0	11
113	Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study. <i>Lancet, The</i> , 2019, 393, 889-898.	6.3	99
114	Anti-Ebola therapy for patients with Ebola virus disease: a systematic review. <i>BMC Infectious Diseases</i> , 2019, 19, 376.	1.3	30
115	Convalescent plasma therapy for persistent hepatitis E virus infection. <i>Journal of Hepatology</i> , 2019, 71, 434-438.	1.8	17
116	A field effect transistor modified with reduced graphene oxide for immunodetection of Ebola virus. <i>Mikrochimica Acta</i> , 2019, 186, 223.	2.5	74
117	Pre-transfusion testing for Ebola virus disease patients in serious communicable infectious diseases hospitals in Tokyo: A cross-sectional study. <i>Journal of Infection and Chemotherapy</i> , 2019, 25, 489-493.	0.8	1
118	Evaluating Promising Investigational Medical Countermeasures: Recommendations in the Absence of Guidelines. <i>Health Security</i> , 2019, 17, 46-53.	0.9	5
119	Ebola virus disease. <i>Lancet, The</i> , 2019, 393, 936-948.	6.3	305
120	Transmission, Human Population, and Pathogenicity: the Ebola Case in Point. , 2019, , 263-278.		0

#	ARTICLE	IF	CITATIONS
121	Ebola Virus Disease. <i>Infectious Disease Clinics of North America</i> , 2019, 33, 953-976.	1.9	36
122	A meta-analysis of clinical studies conducted during the West Africa Ebola virus disease outbreak confirms the need for randomized control groups. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	21
123	Equine-Origin Immunoglobulin Fragments Protect Nonhuman Primates from Ebola Virus Disease. <i>Journal of Virology</i> , 2019, 93, .	1.5	14
124	Perspectives towards antiviral drug discovery against Ebola virus. <i>Journal of Medical Virology</i> , 2019, 91, 2029-2048.	2.5	35
125	Ebola virus disease: An emerging and re-emerging viral threat. <i>Journal of Autoimmunity</i> , 2020, 106, 102375.	3.0	79
126	COVID-19 convalescent plasma clears SARS-CoV-2 refractory to remdesivir in an infant with congenital heart disease. <i>Blood Advances</i> , 2020, 4, 4278-4281.	2.5	23
127	Contemporary Understanding of Ebola and Zika Virus in Pregnancy. <i>Clinics in Perinatology</i> , 2020, 47, 835-846.	0.8	3
128	Understanding the dynamics of COVID-19; implications for therapeutic intervention, vaccine development and movement control. <i>British Journal of Biomedical Science</i> , 2020, 77, 168-184.	1.2	12
129	Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial). <i>BMJ, The</i> , 2020, 371, m3939.	3.0	569
130	Convalescent plasma therapy: a promising coronavirus disease 2019 treatment strategy. <i>Open Biology</i> , 2020, 10, 200174.	1.5	15
131	Severity score for predicting in-facility Ebola treatment outcome. <i>Annals of Epidemiology</i> , 2020, 49, 68-74.	0.9	4
132	To B or Not to B: Mechanisms of Protection Conferred by rVSV-EBOV-GP and the Roles of Innate and Adaptive Immunity. <i>Microorganisms</i> , 2020, 8, 1473.	1.6	12
133	The efficacy assessment of convalescent plasma therapy for COVID-19 patients: a multi-center case series. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 219.	7.1	37
134	Immune response in COVID-19: A review. <i>Journal of Infection and Public Health</i> , 2020, 13, 1619-1629.	1.9	281
135	Efficacy and safety of transfusing plasma from COVID-19 survivors to COVID-19 victims with severe illness. A double-blinded controlled preliminary study. <i>Egyptian Journal of Anaesthesia</i> , 2020, 36, 264-272.	0.2	19
136	RISE OF COVID 19 PANDEMIC: MANAGEMENT STRATEGIES AND EFFECT ON HUMAN HEALTH AND WEALTH. <i>International Research Journal of Pharmacy</i> , 2020, 11, 23-32.	0.0	0
137	The Assessment of Convalescent Plasma Efficacy against COVID-19. <i>Med</i> , 2020, 1, 66-77.	2.2	17
138	<p>Convalescent Plasma Therapy for Management of COVID-19: Perspectives and Deployment in the Current Global Pandemic</p>. <i>Risk Management and Healthcare Policy</i> , 2020, Volume 13, 2707-2728.	1.2	14

#	ARTICLE	IF	CITATIONS
139	COVID-19: The Immune Responses and Clinical Therapy Candidates. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5559.	1.8	25
140	Coronavirus disease 2019 (COVID-19): Immunological approaches and emerging pharmacologic treatments. <i>International Immunopharmacology</i> , 2020, 88, 106885.	1.7	30
141	Lessons learned from early compassionate use of convalescent plasma on critically ill patients with COVID-19. <i>Transfusion</i> , 2020, 60, 2210-2216.	0.8	22
142	Pipeline Pharmacological Therapies in Clinical Trial for COVID-19 Pandemic: a Recent Update. <i>Current Pharmacology Reports</i> , 2020, 6, 228-240.	1.5	17
143	Placental transfer and safety in pregnancy of medications under investigation to treat coronavirus disease 2019. <i>American Journal of Obstetrics & Gynecology MFM</i> , 2020, 2, 100159.	1.3	34
144	Neutrophil Extracellular Traps (NETs) and Damage-Associated Molecular Patterns (DAMPs): Two Potential Targets for COVID-19 Treatment. <i>Mediators of Inflammation</i> , 2020, 2020, 1-25.	1.4	129
145	Addressing the "What do we have to lose? Just give the drug" rationale: making the case for clinical trials and against off-label use in COVID-19. <i>Journal of Thoracic Disease</i> , 2020, 12, 3031-3034.	0.6	1
146	Rapid establishment of a COVID-19 convalescent plasma program in a regional health care delivery network. <i>Transfusion</i> , 2020, 60, 2203-2209.	0.8	10
147	Recent advances in use of fresh frozen plasma, cryoprecipitate, immunoglobulins, and clotting factors for transfusion support in patients with hematologic disease. <i>Seminars in Hematology</i> , 2020, 57, 73-82.	1.8	15
148	Treatment of Coronavirus Disease 2019 Patients with Convalescent Plasma Reveals a Signal of Significantly Decreased Mortality. <i>American Journal of Pathology</i> , 2020, 190, 2290-2303.	1.9	197
149	Treatment of COVID-19 with convalescent plasma: lessons from past coronavirus outbreaks. <i>Clinical Microbiology and Infection</i> , 2020, 26, 1436-1446.	2.8	69
150	US Food and Drug Administration (FDA) Emergency Use Authorization: Glass Half Full or Glass Half Empty?. <i>Clinical Infectious Diseases</i> , 2021, 73, 549-552.	2.9	5
151	Current status and practical considerations in the development of convalescent plasma as a treatment for COVID-19. <i>ISBT Science Series</i> , 2020, 15, 403-414.	1.1	0
152	COVID-19: an update on diagnostic and therapeutic approaches. <i>BMB Reports</i> , 2020, 53, 191-205.	1.1	72
153	Convalescent plasma therapy for coronavirus infection: experience from MERS and application in COVID-19. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 2973-2979.	1.4	5
154	Recommendations for prenatal, intrapartum, and postpartum care during COVID-19 pandemic in India. <i>American Journal of Reproductive Immunology</i> , 2020, 84, e13336.	1.2	7
155	A complement component C1q-mediated mechanism of antibody-dependent enhancement of Ebola virus infection. <i>PLoS Neglected Tropical Diseases</i> , 2020, 14, e0008602.	1.3	11
156	Immune responses during COVID-19 infection. <i>Oncolmmunology</i> , 2020, 9, 1807836.	2.1	103

#	ARTICLE	IF	CITATIONS
157	Supply and demand for plasma-derived medicinal products – A critical reassessment amid the COVID-19 pandemic. <i>Transfusion</i> , 2020, 60, 2748-2752.	0.8	36
158	What are the drugs having potential against COVID-19?. <i>Medicinal Chemistry Research</i> , 2020, 29, 1935-1955.	1.1	8
159	Evaluating the Association of Clinical Characteristics With Neutralizing Antibody Levels in Patients Who Have Recovered From Mild COVID-19 in Shanghai, China. <i>JAMA Internal Medicine</i> , 2020, 180, 1356.	2.6	211
160	A Review of Treatment of Coronavirus Disease 2019 (COVID-19): Therapeutic Repurposing and Unmet Clinical Needs. <i>Frontiers in Pharmacology</i> , 2020, 11, 584956.	1.6	51
161	SARS-CoV-2: Immune Response Elicited by Infection and Development of Vaccines and Treatments. <i>Frontiers in Immunology</i> , 2020, 11, 569760.	2.2	30
162	Convalescent Plasma Therapy for COVID-19: Current Status and Future Directions. <i>Journal of Neuroanaesthesiology and Critical Care</i> , 2020, 7, 140-147.	0.1	1
163	A current review of COVID-19 for the cardiovascular specialist. <i>American Heart Journal</i> , 2020, 226, 29-44.	1.2	97
164	Convalescent plasma: possible therapy for novel coronavirus disease 2019. <i>Transfusion</i> , 2020, 60, 1078-1083.	0.8	24
165	COVID-19 as an Acute Inflammatory Disease. <i>Journal of Immunology</i> , 2020, 205, 12-19.	0.4	133
166	Convalescent plasma therapy: A passive therapy for an aggressive COVID-19. <i>Journal of Medical Virology</i> , 2020, 92, 2251-2253.	2.5	17
167	Ebola. <i>New England Journal of Medicine</i> , 2020, 382, 1832-1842.	13.9	128
168	Convalescent plasma to treat coronavirus disease 2019 (COVID-19): considerations for clinical trial design. <i>Transfusion</i> , 2020, 60, 1123-1127.	0.8	37
169	Convalescent plasma in Covid-19: Possible mechanisms of action. <i>Autoimmunity Reviews</i> , 2020, 19, 102554.	2.5	401
170	Global efforts on vaccines for COVID-19: Since, sooner or later, we all will catch the coronavirus. <i>Journal of Biosciences</i> , 2020, 45, 1.	0.5	39
171	SARS-CoV-2, More than a Respiratory Virus: Its Potential Role in Neuropathogenesis. <i>ACS Chemical Neuroscience</i> , 2020, 11, 1887-1899.	1.7	41
172	SARS-CoV-2 Inflammatory Syndrome. Clinical Features and Rationale for Immunological Treatment. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3377.	1.8	61
173	A Forgotten Episode of Marburg Virus Disease: Belgrade, Yugoslavia, 1967. <i>Microbiology and Molecular Biology Reviews</i> , 2020, 84, .	2.9	32
174	Research Progress of Drug Treatment in Novel Coronavirus Pneumonia. <i>AAPS PharmSciTech</i> , 2020, 21, 130.	1.5	6

#	ARTICLE	IF	CITATIONS
175	Treatment of Coronavirus Disease 2019 (COVID-19) Patients with Convalescent Plasma. American Journal of Pathology, 2020, 190, 1680-1690.	1.9	239
176	Potential specific therapies in COVID-19. Therapeutic Advances in Respiratory Disease, 2020, 14, 175346662092685.	1.0	18
177	<scp>SARSâ€CoVâ€2</scp> in the context of past coronaviruses epidemics: Consideration for prenatal care. Prenatal Diagnosis, 2020, 40, 1641-1654.	1.1	22
178	Treatment algorithm for COVID-19: a multidisciplinary point of view. Clinical Rheumatology, 2020, 39, 2077-2084.	1.0	38
179	Passive antibody therapy in COVID-19. Nature Reviews Immunology, 2020, 20, 401-403.	10.6	93
180	Possible therapeutic agents for COVID-19: a comprehensive review. Expert Review of Anti-Infective Therapy, 2020, 18, 1005-1020.	2.0	24
181	Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. Science, 2020, 369, 643-650.	6.0	1,104
182	Acute Kidney Injury in the 2019 Novel Coronavirus Disease. Kidney Diseases (Basel, Switzerland), 2020, 6, 318-323.	1.2	47
183	Characterization of Ebola convalescent plasma donor immune response and psoralen treated plasma in the United States. Transfusion, 2020, 60, 1024-1031.	0.8	32
184	Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. JAMA - Journal of the American Medical Association, 2020, 323, 1582.	3.8	1,921
185	Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19). Intensive Care Medicine, 2020, 46, 854-887.	3.9	1,536
186	Collecting and evaluating convalescent plasma for COVIDâ€™19 treatment: why and how?. Vox Sanguinis, 2020, 115, 488-494.	0.7	128
187	Insight into 2019 novel coronavirus â€” An updated interim review and lessons from SARS-CoV and MERS-CoV. International Journal of Infectious Diseases, 2020, 94, 119-124.	1.5	337
188	Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 9490-9496.	3.3	1,601
189	Mitigating Coronavirus-Induced Acute Respiratory Distress Syndrome by Radiotherapy. IScience, 2020, 23, 101215.	1.9	12
190	Drug treatment of coronavirus disease 2019 (COVID-19) in China.. European Journal of Pharmacology, 2020, 883, 173326.	1.7	21
191	Investigational Therapies for the Treatment of COVID-19: Updates from Ongoing Clinical Trials. European Urology Focus, 2020, 6, 1028-1031.	1.6	5
192	A potentially effective treatment for COVID-19: A systematic review and meta-analysis of convalescent plasma therapy in treating severe infectious disease. International Journal of Infectious Diseases, 2020, 98, 334-346.	1.5	58

#	ARTICLE	IF	CITATIONS
193	Convalescent plasma therapy in patients with COVID-19. <i>Journal of Clinical Apheresis</i> , 2020, 35, 367-373.	0.7	29
194	Severe refractory COVID-19 patients responding to convalescent plasma; A case series. <i>Annals of Medicine and Surgery</i> , 2020, 56, 125-127.	0.5	41
195	Life-saving effect of convalescent plasma treatment in covid-19 disease: Clinical trial from eastern Anatolia. <i>Transfusion and Apheresis Science</i> , 2020, 59, 102867.	0.5	50
196	Transfusion Service Response to the COVID-19 Pandemic. <i>American Journal of Clinical Pathology</i> , 2020, 154, 280-285.	0.4	22
197	Pregnancy and breastfeeding in the context of Ebola: a systematic review. <i>Lancet Infectious Diseases</i> , The, 2020, 20, e149-e158.	4.6	30
198	The Emerging Role of Convalescent Plasma in the Treatment of COVID-19. <i>HemaSphere</i> , 2020, 4, e409.	1.2	42
199	Novel viruses, old data, and basic principles: how to save lives and avoid harm amid the unknown. <i>Lancet Respiratory Medicine</i> , the, 2020, 8, 661-663.	5.2	10
200	Randomization amid a pandemic – a critical appraisal regarding convalescent plasma therapy clinical trials for COVID-19 patients. <i>ISBT Science Series</i> , 2020, 15, 417-418.	1.1	2
201	The COVID-19 pandemic: biological evolution, treatment options and consequences. <i>Innovative Infrastructure Solutions</i> , 2020, 5, 1.	1.1	14
202	Ebola virus disease. <i>Nature Reviews Disease Primers</i> , 2020, 6, 13.	18.1	340
203	Antibody therapies for the treatment of COVID-19. <i>Antibody Therapeutics</i> , 2020, 3, 101-108.	1.2	10
204	Humoral Immune Responses in COVID-19 Patients: A Window on the State of the Art. <i>Frontiers in Immunology</i> , 2020, 11, 1049.	2.2	88
205	Coronavirus disease 2019 (COVID-19): current status and future perspectives. <i>International Journal of Antimicrobial Agents</i> , 2020, 55, 105951.	1.1	797
206	The epidemiology, diagnosis and treatment of COVID-19. <i>International Journal of Antimicrobial Agents</i> , 2020, 55, 105955.	1.1	672
207	Coronavirus drugs: Using plasma from recovered patients as a treatment for COVID-19. <i>International Journal of Risk and Safety in Medicine</i> , 2020, 31, 47-51.	0.3	29
208	Convalescent Plasma: Therapeutic Hope or Hopeless Strategy in the SARS-CoV-2 Pandemic. <i>Transfusion Medicine Reviews</i> , 2020, 34, 145-150.	0.9	68
209	COVID-19: Immunology and treatment options. <i>Clinical Immunology</i> , 2020, 215, 108448.	1.4	485
210	Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) - an update on the status. <i>Infection, Genetics and Evolution</i> , 2020, 83, 104327.	1.0	248

#	ARTICLE	IF	CITATIONS
211	The Plasma Mobile, â€A gift from heavenâ€™™: The impact of health technology transfer on trial perceptions and expectations during the Ebola-Tx Trial, Conakry. PLoS Neglected Tropical Diseases, 2020, 14, e0008206.	1.3	1
212	Ongoing Clinical Trials for the Management of the COVID-19 Pandemic. Trends in Pharmacological Sciences, 2020, 41, 363-382.	4.0	311
213	Clinical use of Convalescent Plasma in the COVIDâ€™19 pandemic: a transfusionâ€™focussed gap analysis with recommendations for future research priorities. Vox Sanguinis, 2021, 116, 88-98.	0.7	30
214	Battle against COVID-19: Efficacy of Convalescent Plasma as an emergency therapy. American Journal of Emergency Medicine, 2021, 41, 244-246.	0.7	11
215	Appropriate selection of convalescent plasma donors for COVID-19. Lancet Infectious Diseases, The, 2021, 21, 168-169.	4.6	6
216	Effect of convalescent blood products for patients with severe acute respiratory infections of viral etiology: A systematic review and meta-analysis. International Journal of Infectious Diseases, 2021, 102, 397-411.	1.5	9
217	Treatment of immunocompromised COVIDâ€™19 patients with convalescent plasma. Transplant Infectious Disease, 2021, 23, e13477.	0.7	47
218	Longitudinal antibody and T cell responses in Ebola virus disease survivors and contacts: an observational cohort study. Lancet Infectious Diseases, The, 2021, 21, 507-516.	4.6	26
219	Management of lifeâ€™threatening acute respiratory syndrome and severe pneumonia secondary to COVIDâ€™19 in pregnancy: A case report and literature review. Clinical Case Reports (discontinued), 2021, 9, 137-143.	0.2	5
220	Emergence of ancient convalescent plasma (CP) therapy: To manage COVID-19 pandemic. Transfusion Clinique Et Biologique, 2021, 28, 123-127.	0.2	4
221	COVID-19 convalescent plasma treatment of moderate and severe cases of SARS-CoV-2 infection: A multicenter interventional study. International Journal of Infectious Diseases, 2021, 103, 439-446.	1.5	39
222	Convalescent Plasma for the Treatment of COVID-19: Perspectives of the National Institutes of Health COVID-19 Treatment Guidelines Panel. Annals of Internal Medicine, 2021, 174, 93-95.	2.0	38
223	A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia. New England Journal of Medicine, 2021, 384, 619-629.	13.9	741
224	Clinical outcomes for COVIDâ€™19 patients with diabetes mellitus treated with convalescent plasma transfusion in Wuhan, China. Journal of Medical Virology, 2021, 93, 2321-2331.	2.5	31
225	Challenges of drug development during the COVIDâ€™19 pandemic: Key considerations for clinical trial designs. British Journal of Clinical Pharmacology, 2021, 87, 2170-2185.	1.1	15
226	Transfusion reactions associated with <sc>COVID</sc>â€™19 convalescent plasma therapy for <sc>SARSâ€™CoV</sc>â€™2. Transfusion, 2021, 61, 78-93.	0.8	17
227	Ethical challenges in the COVID-19 research context: a toolkit for supporting analysis and resolution. Ethics and Behavior, 2021, 31, 60-75.	1.3	15
228	Pregnancy and <sc>COVID</sc>â€™19: pharmacologic considerations. Ultrasound in Obstetrics and Gynecology, 2021, 57, 195-203.	0.9	57

#	ARTICLE	IF	CITATIONS
229	Review of Ebola virus disease in children – how far have we come?. Paediatrics and International Child Health, 2021, 41, 12-27.	0.3	5
230	Use of convalescent plasma for COVID-19 in India: A review & practical guidelines. Indian Journal of Medical Research, 2021, 153, 64.	0.4	5
231	COVID-19 Treatment: Drug Safety Prior to Conception and During Pregnancy and Breastfeeding. Geburtshilfe Und Frauenheilkunde, 2021, 81, 46-60.	0.8	7
232	Emerging therapeutics in the management of COVID-19. World Journal of Virology, 2021, 10, 1-29.	1.3	7
233	Safety and Efficacy of Convalescent Plasma for Severe COVID-19: Interim Report of a Multicenter Phase II Study from Saudi Arabia. Saudi Journal of Medicine and Medical Sciences, 2021, 9, 16.	0.3	15
234	Safety of pharmacological options for the management of COVID-19 in pregnant women: An Indian perspective. International Journal of Risk and Safety in Medicine, 2021, 32, 3-17.	0.3	4
235	Analysis of an Ebola virus disease survivor whose host and viral markers were predictive of death indicates the effectiveness of medical countermeasures and supportive care. Genome Medicine, 2021, 13, 5.	3.6	9
236	Understanding COVID-19 Pandemic: Molecular Mechanisms and Potential Therapeutic Strategies. An Evidence-Based Review. Journal of Inflammation Research, 2021, Volume 14, 13-56.	1.6	33
237	Convalescent Plasma Therapy in SARS-COV-2 Infection, Experience in Tucum�n Argentina: An Observational Study. Frontiers in Medical Case Reports, 2021, 02, .	0.0	0
238	Neutralizing Antibody Responses to SARS-CoV-2 in Korean Patients Who Have Recovered from COVID-19. Yonsei Medical Journal, 2021, 62, 584.	0.9	8
239	Severe Acute Respiratory Syndrome Coronavirus 2: Manifestations of Disease and Approaches to Treatment and Prevention in Humans. Comparative Medicine, 2021, 71, 342-358.	0.4	3
240	Recent Developments on Therapeutic and Diagnostic Approaches for COVID-19. AAPS Journal, 2021, 23, 14.	2.2	291
241	Use of Immunoglobulins in the Prevention of Viral Infections. , 2021, , 267-280.		1
242	A look-back at convalescent plasma to treat COVID-19. Transfusion and Apheresis Science, 2021, 60, 103063.	0.5	11
243	COVID-19 pandemic and transfusion medicine: the worldwide challenge and its implications. Annals of Hematology, 2021, 100, 1115-1122.	0.8	20
244	COVID-19 Pandemic: Advances in Diagnosis, Treatment, Organoid Applications and Impacts on Cancer Patient Management. Frontiers in Medicine, 2021, 8, 606755.	1.2	4
245	Proteomics Analysis of Serum from COVID-19 Patients. ACS Omega, 2021, 6, 7951-7958.	1.6	16
246	Neutralization of SARS-CoV-2 with IgG from COVID-19-convalescent plasma. Scientific Reports, 2021, 11, 5563.	1.6	42

#	ARTICLE	IF	CITATIONS
247	Targeting Ebola virus replication through pharmaceutical intervention. Expert Opinion on Investigational Drugs, 2021, 30, 201-226.	1.9	11
248	Blockade of SARS-CoV-2 spike protein-mediated cell-cell fusion using COVID-19 convalescent plasma. Scientific Reports, 2021, 11, 5558.	1.6	19
249	Reviewing the Ethical Concerns of the Convalescent Plasma Therapy in COVID-19. Journal of Laboratory Physicians, 2021, 13, 091-094.	0.4	2
250	Potential therapeutic and pharmacological strategies for SARS-CoV2. Journal of Pharmaceutical Investigation, 2021, 51, 281-296.	2.7	15
251	Effects and Safety of Convalescent Plasma Administration in a Group of Polish Pediatric Patients with COVID-19: A Case Series. Life, 2021, 11, 247.	1.1	8
252	SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface. Nature Communications, 2021, 12, 1577.	5.8	73
253	COVID-19 convalescent plasma composition and immunological effects in severe patients. Journal of Autoimmunity, 2021, 118, 102598.	3.0	92
254	COVID-19 vaccine testing in pregnant females is necessary. Journal of Clinical Investigation, 2021, 131, .	3.9	39
256	Inflammation, immunity and potential target therapy of SARS-COV-2: A total scale analysis review. Food and Chemical Toxicology, 2021, 150, 112087.	1.8	17
257	Convalescent plasma treatment of critically ill intensive care COVID-19 patients. Transfusion, 2021, 61, 1394-1403.	0.8	15
258	Efficacy and safety of convalescent plasma therapy in severe COVID-19 patients with acute respiratory distress syndrome. International Immunopharmacology, 2021, 93, 107239.	1.7	23
259	A Systematic Review on Various Therapeutic Options for Coronavirus Outbreak. Journal of Drug Delivery and Therapeutics, 2021, 11, 185-194.	0.2	0
260	Antibody Therapy: From Diphtheria to Cancer, COVID-19, and Beyond. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, 2021, 40, 36-49.	0.8	8
261	Distinct SARS-CoV-2 antibody reactivity patterns in coronavirus convalescent plasma revealed by a coronavirus antigen microarray. Scientific Reports, 2021, 11, 7554.	1.6	11
262	The Principles of Antibody Therapy for Infectious Diseases with Relevance for COVID-19. MBio, 2021, 12, .	1.8	62
264	Natural Products, a Potential Therapeutic Modality in Management and Treatment of nCoV-19 Infection: Preclinical and Clinical Based Evidence. Current Pharmaceutical Design, 2021, 27, 1153-1169.	0.9	5
265	BLOOD GROUP DISTRIBUTION AMONG COVID-19 CONVALESCENT PLASMA DONORS. , 2021, , 6-7.		0
266	Polyclonal hyper immunoglobulin: A proven treatment and prophylaxis platform for passive immunization to address existing and emerging diseases. Human Vaccines and Immunotherapeutics, 2022, 18, 1-20.	1.4	18

#	ARTICLE	IF	CITATIONS
267	Convalescent plasma to treat COVID-19: Following the Argentinian lead. <i>Transfusion and Apheresis Science</i> , 2021, 60, 103161.	0.5	1
268	Convalescent plasma for adults with acute COVID-19 respiratory illness (CONCOR-1): study protocol for an international, multicentre, randomized, open-label trial. <i>Trials</i> , 2021, 22, 323.	0.7	21
269	Effectiveness of convalescent plasma in Indian patients with COVID-19. <i>Blood Cells, Molecules, and Diseases</i> , 2021, 88, 102548.	0.6	29
270	Evaluation by simulation of clinical trial designs for evaluation of treatment during a viral haemorrhagic fever outbreak. <i>BMC Medical Research Methodology</i> , 2021, 21, 98.	1.4	0
271	Recent Antiviral Treatment and Vaccination Strategies Against SARS-CoV-2. <i>Klinische Monatsblätter Fur Augenheilkunde</i> , 2021, 238, 569-578.	0.3	6
272	The 15-Months Clinical Experience of SARS-CoV-2: A Literature Review of Therapies and Adjuvants. <i>Antioxidants</i> , 2021, 10, 881.	2.2	20
273	Convalescent Plasma Immunotherapy - A Possible Mitigation Strategy for SARS-CoV-2 Pandemic. , 0, , .		0
274	Modeling within-Host SARS-CoV-2 Infection Dynamics and Potential Treatments. <i>Viruses</i> , 2021, 13, 1141.	1.5	48
275	Case Report: Effects of Anti-SARS-CoV-2 Convalescent Antibodies Obtained With Double Filtration Plasmapheresis. <i>Frontiers in Immunology</i> , 2021, 12, 711915.	2.2	2
276	Perspectives on passive antibody therapy and peptide-based vaccines against emerging pathogens like SARS-CoV-2. <i>Germes</i> , 2021, 11, 287-305.	0.5	2
277	Antibody responses to filovirus infections in humans: protective or not?. <i>Lancet Infectious Diseases</i> , The, 2021, 21, e348-e355.	4.6	3
278	Potential therapeutic agents to COVID-19: An update review on antiviral therapy, immunotherapy, and cell therapy. <i>Biomedicine and Pharmacotherapy</i> , 2021, 138, 111518.	2.5	50
279	COVID-19 convalescent plasma: mechanisms of action and rationale for use: a narrative review. <i>Annals of Blood</i> , 0, 6, 16-16.	0.4	1
280	Molecular mechanism of interaction between SARS-CoV-2 and host cells and interventional therapy. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 233.	7.1	203
281	Convalescent plasma therapy for severe Covid-19 in patients with hematological malignancies. <i>Transfusion and Apheresis Science</i> , 2021, 60, 103075.	0.5	21
282	COVID-19 and pregnancy: a narrative review on the use of convalescent plasma. <i>Annals of Blood</i> , 0, 6, 14-14.	0.4	0
283	<scp>COVID</scp>â€19 convalescent plasma cohort study: Evaluation of the association between both donor and recipient neutralizing antibody titers and patient outcomes. <i>Transfusion</i> , 2021, 61, 2295-2306.	0.8	8
284	COVID-19 Pandemic and the Convalescent Plasma Therapy: Possible Benefits and Risks. <i>Current Clinical Microbiology Reports</i> , 2021, 8, 194-198.	1.8	3

#	ARTICLE	IF	CITATIONS
286	Characterization of an Anti-Ebola virus Hyperimmune Globulin Derived from Convalescent Plasma. <i>Journal of Infectious Diseases</i> , 2021, , .	1.9	3
287	Novel coronavirus disease (COVID-19): origin, transmission through the environment, health effects, and mitigation strategies—a review. <i>Environmental Sustainability</i> , 2021, 4, 515-526.	1.4	2
288	What convalescent plasma in treating severe acute respiratory infections of viral aetiology can hint for COVID-19? Evidence from a meta-analysis. <i>Transfusion Clinique Et Biologique</i> , 2021, 28, 321-329.	0.2	1
289	Filovirus Neutralising Antibodies: Mechanisms of Action and Therapeutic Application. <i>Pathogens</i> , 2021, 10, 1201.	1.2	9
290	Antibody and cellular therapies for treatment of covid-19: a living systematic review and network meta-analysis. <i>BMJ, The</i> , 2021, 374, n2231.	3.0	59
291	Detection of SARS-CoV-2-independent immunoregulatory activity of COVID-19 convalescent plasma. <i>Transfusion</i> , 2021, 61, 3087-3093.	0.8	2
292	Novel quinolone derivatives targeting human dihydroorotate dehydrogenase suppress Ebola virus infection in vitro. <i>Antiviral Research</i> , 2021, 194, 105161.	1.9	6
293	Therapeutics development for Ebola virus disease: A recent scenario. <i>Current Opinion in Pharmacology</i> , 2021, 60, 208-215.	1.7	12
294	CONVALESCENT PLASMA THERAPY FOR COVID-19 PATIENTS: REGULATORY GUIDANCE ON COLLECTION, TESTING, PROCESSING, STORAGE, DISTRIBUTION, AND CLINICAL TRIALS. <i>Asian Journal of Pharmaceutical and Clinical Research</i> , 0, , 6-14.	0.3	1
296	Genetic Aspects and Immune Responses in Covid-19: Important Organ Involvement. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1327, 3-22.	0.8	5
297	Immunological perspectives on the pathogenesis, diagnosis, prevention and treatment of COVID-19. <i>Molecular Biomedicine</i> , 2021, 2, 1.	1.7	20
298	An Account of Immune Senescence in the Clinical Pathophysiology of COVID-19 Infection in Aging. , 2021, 12, 662.		4
299	Correlation between SARS-CoV-2 antibody screening by immunoassay and neutralizing antibody testing. <i>Transfusion</i> , 2021, 61, 1181-1190.	0.8	42
300	The outlook for diagnostic purposes of the 2019 novel coronavirus disease. <i>Journal of Cellular Physiology</i> , 2020, 235, 9211-9229.	2.0	35
301	Competition for Medical Supplies Under Stochastic Demand in the Covid-19 Pandemic: A Generalized Nash Equilibrium Framework. <i>Springer Optimization and Its Applications</i> , 2021, , 331-356.	0.6	14
303	Ebola Virus Disease and Pregnancy: Perinatal Transmission and Epidemiology. <i>Global Maternal and Child Health</i> , 2019, , 53-65.	0.1	5
304	Ebola and Pregnant Women: Providing Maternity Care at MSF Treatment Centers. <i>Global Maternal and Child Health</i> , 2019, , 87-101.	0.1	2
305	COVID-19 therapy: What weapons do we bring into battle?. <i>Bioorganic and Medicinal Chemistry</i> , 2020, 28, 115757.	1.4	22

#	ARTICLE	IF	CITATIONS
306	Convalescent plasma: A possible treatment protocol for COVID- 19 patients suffering from diabetes or underlying liver diseases. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2020, 14, 665-669.	1.8	15
307	Coronaviruses pandemics: Can neutralizing antibodies help?. Life Sciences, 2020, 255, 117836.	2.0	24
308	How blood from coronavirus survivors might save lives. Nature, 2020, 580, 16-17.	13.7	16
309	Nonhuman primate to human immunobridging to infer the protective effect of an Ebola virus vaccine candidate. Npj Vaccines, 2020, 5, 112.	2.9	45
310	Different aspects of convalescent plasma therapy for COVID-19 treatment; a critical review. Immunopharmacology and Immunotoxicology, 2021, 43, 30-36.	1.1	5
311	Repurposing therapeutic agents against SARS-CoV-2 infection: most promising and neoteric progress. Expert Review of Anti-Infective Therapy, 2021, 19, 1009-1027.	2.0	23
312	Potential benefits, mechanisms, and uncertainties of convalescent plasma therapy for COVID-19. Blood Science, 2020, 2, 71-75.	0.4	7
313	Surviving Sepsis Campaign: Guidelines on the Management of Critically Ill Adults with Coronavirus Disease 2019 (COVID-19). Critical Care Medicine, 2020, 48, e440-e469.	0.4	816
325	West Africa 2013: Re-examining Ebola. , 0, , 1-37.		1
326	Convalescent Plasma Therapy: A New Flair of Hope in the Fight Against the Novel Corona Virus Pandemic (COVID-19). Nano LIFE, 2021, 11, 2050004.	0.6	1
327	The state of latency in microbial pathogenesis. Journal of Clinical Investigation, 2020, 130, 4525-4531.	3.9	18
328	Effectiveness of Convalescent Plasma Therapy for COVID-19 Patients in Hunan, China. Dose-Response, 2020, 18, 155932582097992.	0.7	11
329	Antiviral efficacy of favipiravir against Ebola virus: A translational study in cynomolgus macaques. PLoS Medicine, 2018, 15, e1002535.	3.9	108
330	Anti-EBOV GP IgGs Lacking $\hat{\pm}$ 1-3-Galactose and Neu5Gc Prolong Survival and Decrease Blood Viral Load in EBOV-Infected Guinea Pigs. PLoS ONE, 2016, 11, e0156775.	1.1	10
331	A Systematic Review of Ebola Treatment Trials to Assess the Extent to Which They Adhere to Ethical Guidelines. PLoS ONE, 2017, 12, e0168975.	1.1	20
332	Efficacy and safety of convalescent plasma for severe COVID-19 based on evidence in other severe respiratory viral infections: a systematic review and meta-analysis. Cmaj, 2020, 192, E745-E755.	0.9	78
334	Hyper-immune/convalescent plasma: an old option and a valid strategy for treatment of COVID-19?. Minerva Medica, 2020, 111, 362-364.	0.3	6
335	Convalescent plasma: a valid option in the treatment of COVID-19?. Insights in Clinical and Cellular Immunology, 2020, 4, 001-002.	0.1	4

#	ARTICLE	IF	CITATIONS
336	Convalescent Plasma Therapy for Coronavirus Disease 2019. <i>Infection and Chemotherapy</i> , 2020, 52, 307.	1.0	10
337	Clinical management of COVID-19. <i>Indian Journal of Medical Research</i> , 2020, 151, 401.	0.4	68
338	The 2019â€“2020 novel coronavirus (severe acute respiratory syndrome coronavirus 2) pandemic: A joint american college of academic international medicine-world academic council of emergency medicine multidisciplinary COVID-19 working group consensus paper. <i>Journal of Global Infectious Diseases</i> , 2020, 12, 47.	0.2	270
339	Case Report: Use of Plasma Exchange Followed by Convalescent Plasma Therapy in a Critically Ill Patient with Severe Fever and Thrombocytopenia Syndromeâ€“Associated Encephalopathy: Cytokine/Chemokine Concentrations, Viral Loads, and Antibody Responses. <i>American Journal of Tropical Medicine and Hygiene</i> , 2018, 99, 1466-1468.	0.6	11
340	Convalescent Plasma Therapy and Its Effects On COVID-19 Patient Outcomes: A Systematic Review of Current Literature. <i>Cureus</i> , 2020, 12, e9535.	0.2	27
341	Kinetics of Neutralizing Antibody Response Underscores Clinical COVID-19 Progression. <i>Journal of Immunology Research</i> , 2021, 2021, 1-11.	0.9	4
342	Building a better antibody through the Fc: advances and challenges in harnessing antibody Fc effector functions for antiviral protection. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 4328-4344.	1.4	13
343	Clinical drug therapies and biologicals currently used or in clinical trial to treat COVID-19. <i>Biomedicine and Pharmacotherapy</i> , 2021, 144, 112276.	2.5	9
344	Donor Screening and Deferral. <i>Clinics in Laboratory Medicine</i> , 2021, 41, 563-577.	0.7	0
345	Viral Hemorrhagic Fevers. , 0, , 141-150.		0
346	Filoviruses. , 0, , 981-1007.		1
347	Ebola Virus Disease: Therapeutic and Potential Preventative Opportunities. , 0, , 53-71.		1
348	Society of Internal Medicine, 2017, 106, 405-408.	0.0	0
349	Viral Hemorrhagic Fever Preparedness. , 2018, , 197-211.		0
350	Ebola Hemorrhagic Fever: Recent Update On Disease Status, Current Therapies And Advances In Treatment. <i>Journal of Pharmaceutical Technology Research and Management</i> , 2017, 5, 217-234.	0.3	1
351	Simmering to the End (January 2015â€“June 2016). , 2018, , 227-310.		0
352	Ebola Virus Disease in the Obstetric Population. , 2018, , 87-144.		1
353	Engager (avec) les communautÃ©s dans un essai vaccinal en contexte post-Ebola (GuinÃ©e Conakry)Â: un modÃ©le basÃ© sur les Â«ÂchampionsÂ». <i>Sciences Et Actions Sociales</i> , 2018, NÂ° 10, 112-141.	0.1	4

#	ARTICLE	IF	CITATIONS
375	Effectiveness and Controversy of Convalescent Plasma Therapy for Coronavirus Disease 2019 Patients. <i>Infectious Diseases & Immunity</i> , 2021, Publish Ahead of Print, .	0.2	2
378	A Multiclass, Multiproduct Covid-19 Convalescent Plasma Donor Equilibrium Model. <i>SN Operations Research Forum</i> , 2021, 2, 1.	0.6	3
379	Plasma therapy: a passive resistance against the deadliest. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-10.	1.4	5
380	Evaluation of the efficacy of immune plasma treatment in COVID-19 infected intensive care unit patients. <i>Iberoamerican Journal of Medicine</i> , 0, , 37-44.	0.1	0
381	Experience with COVID-19 convalescent plasma provides vital guidance to future pandemics. <i>Transfusion</i> , 2022, 62, 681-684.	0.8	6
382	Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebo-controlled, multicentre Phase II clinical trial. <i>PLoS Medicine</i> , 2022, 19, e1003865.	3.9	27
383	Lessons learned from the use of convalescent plasma for the treatment of COVID-19 and specific considerations for immunocompromised patients. <i>Transfusion and Apheresis Science</i> , 2022, 61, 103355.	0.5	9
384	The Role of Disease Severity and Demographics in the Clinical Course of COVID-19 Patients Treated With Convalescent Plasma. <i>Frontiers in Medicine</i> , 2021, 8, 707895.	1.2	3
385	The "Invisible Enemy" SARS-CoV-2: Viral Spread and Drug Treatment. <i>Medicina (Lithuania)</i> , 2022, 58, 261.	0.8	3
386	Convalescent plasma in hospitalized patients with COVID-19 pneumonia: a case-control prospective study. <i>Rivista Italiana Della Medicina Di Laboratorio</i> , 0, , .	0.2	0
387	Safety of convalescent plasma therapy for COVID-19 patients and analysis of viral kinetics: a single-center, open-label, single-arm, interventional study in Japan. <i>GHM Open</i> , 2022, 2, 38-43.	0.1	4
388	Use of Early Donated COVID-19 Convalescent Plasma Is Optimal to Preserve the Integrity of Lymphatic Endothelial Cells. <i>Pharmaceuticals</i> , 2022, 15, 365.	1.7	2
389	The Quality of Anti-SARS-CoV-2 T Cell Responses Predicts the Neutralizing Antibody Titer in Convalescent Plasma Donors. <i>Frontiers in Public Health</i> , 2022, 10, 816848.	1.3	6
390	Designing and implementing methodology for double-blind, placebo-controlled clinical trials using blood products within the Department of Veterans Affairs. <i>Clinical Trials</i> , 2022, 19, 137-145.	0.7	1
391	Mortality reduction in pediatric patients with severe fatal human adenoviral pneumonia treated with high titer neutralizing antibodies (NAbs) plasma: a retrospective cohort study. <i>BMC Pediatrics</i> , 2022, 22, 151.	0.7	2
392	Vaccine-Associated Enhanced Disease and Pathogenic Human Coronaviruses. <i>Frontiers in Immunology</i> , 2022, 13, 882972.	2.2	32
393	Treatment of severe COVID-19 patients with either low- or high-volume of convalescent plasma versus standard of care: A multicenter Bayesian randomized open-label clinical trial (COOP-COVID-19-MCTI). <i>The Lancet Regional Health Americas</i> , 2022, 10, 100216.	1.5	7
394	The discovery and development of novel treatment strategies for filoviruses. <i>Expert Opinion on Drug Discovery</i> , 2022, 17, 139-149.	2.5	9

#	ARTICLE	IF	CITATIONS
395	Development of Web Based Online One Stop Platform to Fight Covid-19. , 2021, , .		0
396	Immunization against severe acute respiratory syndrome Coronavirus 2: an overview. African Health Sciences, 2021, 21, 1574-83.	0.3	2
397	Ebola virus disease in pregnancy: a systematic review and meta-analysis. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2022, 116, 509-522.	0.7	4
398	Convalescent plasma for treatment of COVID-19: study protocol for an open randomised controlled trial in Sweden. BMJ Open, 2021, 11, e048337.	0.8	2
399	â€˜Convalescent Plasmaâ€™- An Effective Treatment Option to Prevent Emerging nCOVID-19- A Review. Infectious Disorders - Drug Targets, 2022, 22, .	0.4	0
401	Preservation of anti-SARS-CoV-2 neutralising antibodies in convalescent plasma after pathogen reduction with methylene blue and visible light. Blood Transfusion, 2021, , .	0.3	4
402	The Effect of Convalescent Plasma in Patients With Covid-19 in Intensive Care Unit. In Vivo, 2022, 36, 1342-1348.	0.6	0
403	Efficacy and Safety of Blood Derivative Therapy for Patients with COVID-19: A Systematic Review and Meta-Analysis. Transfusion Medicine and Hemotherapy, 2022, 49, 388-400.	0.7	3
404	Mechanisms of phosphatidylserine influence on viral production: A computational model of Ebola virus matrix protein assembly. Journal of Biological Chemistry, 2022, 298, 102025.	1.6	4
405	Convalescent Plasma - A Review of this Potential Therapeutic Strategy for Combating Novel Coronavirus Disease 2019. Asian Pacific Journal of Health Sciences, 2021, 8, 99-103.	0.0	0
406	Prospective Medicinal Plants and Their Phytochemicals Shielding Autoimmune and Cancer Patients Against the SARS-CoV-2 Pandemic: A Special Focus on Matcha. Frontiers in Oncology, 2022, 12, .	1.3	5
407	A Multi-Center, Open-Label, Randomized Controlled Trial to Evaluate the Efficacy of Convalescent Plasma Therapy for Coronavirus Disease 2019: A Trial Protocol (COVIPLA-RCT). Life, 2022, 12, 856.	1.1	4
409	PROSPECTS FOR IMMUNOTHERAPY TREATMENT AGAINST COVID-19 INFECTION. Ek'sperimentuli Da Klinikuri Medic'ina, 0, , .	0.0	0
410	Convalescent plasma â€˜ An insight into a novel treatment of covid-19 ICU patients. Transfusion and Apheresis Science, 2022, 61, 103497.	0.5	2
411	A review of mass spectrometryâ€‘based analyses to understand COVIDâ€‘19 convalescent plasma mechanisms of action. Proteomics, 0, , 2200118.	1.3	3
412	Analysis of 52â€‘%240 source plasma donors of convalescent <scp>COVID</scp>â€‘19 plasma: Sex, ethnicity, and age association with initial antibody levels and rate of dissipation. Journal of Clinical Apheresis, 2022, 37, 449-459.	0.7	5
413	A Historical Review of Military Medical Strategies for Fighting Infectious Diseases: From Battlefields to Global Health. Biomedicines, 2022, 10, 2050.	1.4	8
414	Bridging Animal and Human Data in Pursuit of Vaccine Licensure. Vaccines, 2022, 10, 1384.	2.1	3

#	ARTICLE	IF	CITATIONS
415	The effect of convalescent plasma on the treatment of COVID-19 patients in Ardabil, Iran. <i>Journal of Education and Health Promotion</i> , 2022, 11, 266.	0.3	0
416	Efficacy of COVID-19 Convalescent Plasma Based on Antibody Concentration. <i>Advances in Hematology</i> , 2022, 2022, 1-11.	0.6	3
417	Use of convalescent plasma in pregnant women with early stage COVID-19 infection in a tertiary care hospital in Dubai, February to March 2021: a case series study. <i>BMC Pregnancy and Childbirth</i> , 2022, 22, .	0.9	1
418	The number of cases, mortality and treatments of viral hemorrhagic fevers: A systematic review. <i>PLoS Neglected Tropical Diseases</i> , 2022, 16, e0010889.	1.3	6
419	Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients—An Open-Label Phase II Clinical Trial. <i>Life</i> , 2022, 12, 1565.	1.1	1
421	Convalescent Plasma to Treat COVID-19: A Two-Center, Randomized, Double-Blind Clinical Trial. <i>Life</i> , 2022, 12, 1767.	1.1	2
422	Convalescent plasma in hospitalized pediatric and obstetric coronavirus disease 2019 (<sc>COVID</sc>â€”19) patients. <i>Pediatrics International</i> , 2022, 64, .	0.2	2
423	CONVALESCENT PLASMA: ITS EFFECTIVENESS IN TREATING MODERATE AND SEVERE CASES OF COVID 19 IN A TERTIARY CARE CENTRE IN UTTARAKHAND. , 2022, , 12-14.		0
424	Impact of Convalescent Plasma Therapy in Hospitalized Patients With Severe COVID-19. <i>Infectious Diseases in Clinical Practice</i> , 2022, 30, 1-6.	0.1	0
425	Use of convalescent plasma therapy in hospitalised adult patients with non-critical COVID-19: a focus on the elderly from Hungary. <i>GeroScience</i> , 0, , .	2.1	1
426	White paper on pandemic preparedness in the blood supply. <i>Vox Sanguinis</i> , 2023, 118, 8-15.	0.7	4
427	Antiviral Treatment of COVID-19 Pneumonia. <i>Clinics in Chest Medicine</i> , 2022, , .	0.8	0
428	Revisiting Ebola: Lessons learned from the 2014â€”2015. <i>Transfusion</i> , 2023, 63, 427-429.	0.8	1
429	Early Treatment with Monoclonal Antibodies or Convalescent Plasma Reduces Mortality in Non-Vaccinated COVID-19 High-Risk Patients. <i>Viruses</i> , 2023, 15, 119.	1.5	6
431	Evaluation of Convalescent Plasma in the Management of Critically Ill COVID-19 Patients (with No) Tj ETQq0 0 0 rgBT ₁ /Overlock 10 Tf 50		2
432	Protective roles and protective mechanisms of neutralizing antibodies against SARS-CoV-2 infection and their potential clinical implications. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	14
433	Effectiveness of COVID-19 Convalescent Plasma (CCP) During the Pandemic Era: A Literature Review. <i>Journal of Blood Medicine</i> , 0, Volume 14, 159-187.	0.7	2
442	Traditional Herbal Medicines: A Prospective Panacea for SARS-CoV-2. , 2023, , 25-52.		0

#	ARTICLE	IF	CITATIONS
443	Ebola Vaccines. , 2023, , 311-329.e6.		0
447	Clinical Characteristics, Diagnosis, and Therapeutics of COVID-19: A Review. Current Medical Science, 2023, 43, 1066-1074.	0.7	4
454	Ebola and Marburg viruses. , 2024, , 2281-2308.		0